Industries > Pharma > Antibacterial Drugs Market Report 2021-2031
Antibacterial Drugs Market Report 2021-2031
Forecasts By Drug Class(B-lactam, Cephalosporin, Quinolones, Carbapenems, Penicillin, Macrolides, Fluoroquinolones, Tetracyclines, Aminoglycosides, Sulfonamides, Phenicols and Others), By Prescription Type( OTC Antibacterial Drugs and Prescription based Antibacterial Drugs), By Route of Administration (Oral, Topical, and Parenteral, and Others), By Drug Type (Generic drugs, and Branded drugs) By Indication (Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, Complicated Urinary Tract Infections and Others) By End-User(Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacy, Retail pharmacy, Ecommerce and Others) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios
Antibacterial Drugs Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Antibacterial Drugs is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 250+ page report provides 490+ tables and 475+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Antibacterial Drugs Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Revenue and growth forecasts from 2021 to 2031 for the Global Antibacterial Drugs Market By Drug Class
• B-lactam
• Cephalosporins
o Rocephin
o Sulperazon
o Ceftin/Zinnat
o Meiact
o Flomox
o Teflaro, Zeftera
o Ceftolozane-tazobactam
o Ceftazidime-Avibactam
• Quinolones
• Carbapenems
o Invanz
o Merrem/Meropen
o Primaxin
o Doribax
• Penicillins
o Generic amoxicillin
o Augmentin
o Zosyn/Tazocin
o Unasyn
o Generic amoxicllin-clavulanic acid
o Amoxil
• Macrolides
o Biaxin/Clarith
o Zithromax
o Dalacin
o Dificid
o Solithromycin
• Fluoroquinolones
o Avelox
o Cravit
o Vigamox
o Ciprodex
o Cipro/Ciprobay
o Geninax
o Defafloxacin
• Tetracyclines
• Aminoglycosides
• Sulfonamides
• Phenicols
• Others
Revenue and growth forecasts from 2021 to 2031 for the Global Antibacterial Drugs Market By Prescription type
• OTC Antibacterial Drugs
• Prescription-based Antibacterial Drugs
Revenue and growth forecasts from 2021 to 2031 for the Global Antibacterial Drugs Market By Drug Type
• Generic Drugs
• Branded Drugs
Revenue and growth forecasts from 2021 to 2031 for the Global Antibacterial Drugs Market By Indication
• Hospital-Acquired Bacterial Pneumonia
• Ventilator-Associated Bacterial Pneumonia
• Urinary Tract Infections
• Others
Revenue and growth forecasts from 2021 to 2031 for the Global Antibacterial Drugs Market By Route of Administration
• Oral
• Topical
• Parenteral
• Others
Revenue and growth forecasts from 2021 to 2031 for the Global Antibacterial Drugs Market By End-User
• Hospitals
• Homecare
• Specialty Clinics
• Others
Revenue and growth forecasts from 2021 to 2031 for the Global Antibacterial Drugs Market by Distribution Channel
• Hospital Pharmacy
• Retail pharmacy
• Online Pharmacy
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Antibacterial Drugs Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Antibacterial Drugs Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Antibacterial Drugs Market report helps you
In summary, our 500+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Antibacterial Drugs Market, with forecasts for Get our report today Antibacterial Drugs Market Forecast 2021-2031: By Drug Class, Prescription Type, Drug Type, Route of Administration, Indication, End-User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Antibacterial Drugs market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Antibacterial Drugs Market. Some of the company’s profiled in this report include
• Adenium Biotech ApS
• Allecra Therapeutics GmbH
• AstraZeneca
• Bayer
• BioVersys AG
• Eli Lilly
• GlaxoSmithKline (GSK)
• Merck & Co.
• Novartis
• Pfizer
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Antibacterial Drugs Market Report 2021-2031: Forecasts By Drug Class(B-lactam, Cephalosporin, Quinolones, Carbapenems, Penicillin, Macrolides, Fluoroquinolones, Tetracyclines, Aminoglycosides, Sulfonamides, Phenicols and Others), By Prescription Type( OTC Antibacterial Drugs and Prescription based Antibacterial Drugs), By Route of Administration (Oral, Topical, and Parenteral, and Others), By Drug Type (Generic drugs, and Branded drugs) By Indication (Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, Complicated Urinary Tract Infections and Others) By End-User(Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacy, Retail pharmacy, Ecommerce and Others) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Antibacterial Drugs Market
2.1. Antibacterial Drugs Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Prescription Type Submarkets Definitions
3. Antibacterial Drugs Market Overview
3.1. Global Antibacterial Drugs Market Size and Forecast by Region
3.2. Global Antibacterial Drugs Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of bacterial diseases
3.3.1.2. Increasing consumptions of tobacco products
3.3.1.3. Growing number of FDA approvals coupled with launch of new products
3.3.1.4. Therapeutic advancements in antibacterial drugs
3.3.2. Market Restraints
3.3.2.1. Adherence to stringent regulatory norms
3.3.2.2. High cost of development
3.3.2.3. Product recall
3.3.3. Opportunities
3.3.3.1. Increasing strategic initiatives in antibacterial drugs market
3.3.3.2. Growing demand in emerging economies
3.3.4. Challenges
3.3.4.1. Increasing risk of side effects associated with antibacterial drugs
3.3.4.2. Increasing prices of API
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Antibacterial Drugs Market Analysis and Forecast 2021-2031, By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. B-lactam
4.1.1.1. B-lactam market size and forecast, 2021-2031 (USD Million)
4.1.2. Cephalosporin
4.1.2.1. Cephalosporin market size and forecast, 2021-2031 (USD Million)
4.1.3. Quinolones
4.1.3.1. Quinolones market size and forecast, 2021-2031 (USD Million)
4.1.4. Carbapenems
4.1.4.1. Carbapenems market size and forecast, 2021-2031 (USD Million)
4.1.5. Penicillin
4.1.5.1. Penicillin market size and forecast, 2021-2031 (USD Million)
4.1.6. Macrolides
4.1.6.1. Macrolides market size and forecast, 2021-2031 (USD Million)
4.1.7. Fluoroquinolones
4.1.7.1. Fluoroquinolones market size and forecast, 2021-2031 (USD Million)
4.1.8. Tetracyclines
4.1.8.1. Tetracyclines market size and forecast, 2021-2031 (USD Million)
4.1.9. Aminoglycosides
4.1.9.1. Aminoglycosides market size and forecast, 2021-2031 (USD Million)
4.1.10. Sulfonamides
4.1.10.1. Sulfonamides market size and forecast, 2021-2031 (USD Million)
4.1.11. Phenicols
4.1.11.1. Phenicols market size and forecast, 2021-2031 (USD Million)
4.1.12. Others
4.1.12.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 By Prescription Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. OTC Antibacterial Drugs
5.1.1.1. OTC Antibacterial Drugs market size and forecast, 2021-2031 (USD Million)
5.1.2. Prescription based Antibacterial Drugs
5.1.2.1. Prescription based Antibacterial Drugs market size and forecast, 2021-2031 (USD Million)
6. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Approved-Drugs
6.1.1.1. Approved-Drugs market size and forecast, 2021-2031 (USD Million)
6.1.2. Off-label Drugs
6.1.2.1. Off-label Drugs market size and forecast, 2021-2031 (USD Million)
7. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 By Route of Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Oral
7.1.1.1. Oral market size and forecast, 2021-2031 (USD Million)
7.1.2. Topical
7.1.2.1. Topical market size and forecast, 2021-2031 (USD Million)
7.1.3. Parenteral
7.1.3.1. Parenteral market size and forecast, 2021-2031 (USD Million)
7.1.4. Others
7.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Generic Drugs
8.1.1.1. Generic Drugs market size and forecast, 2021-2031 (USD Million)
8.1.2. Branded Drugs
8.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
9. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 By Indication (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospital-Acquired Bacterial Pneumonia
9.1.1.1. Hospital-Acquired Bacterial Pneumonia market size and forecast, 2021-2031 (USD Million)
9.1.2. Ventilator-Associated Bacterial Pneumonia
9.1.2.1. Ventilator-Associated Bacterial Pneumonia market size and forecast, 2021-2031 (USD Million)
9.1.3. Complicated Urinary Tract Infections
9.1.3.1. Complicated Urinary Tract Infections market size and forecast, 2021-2031 (USD Million)
9.1.4. Others
9.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
10. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 by End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Hospitals
10.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
10.1.2. Homecare
10.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
10.1.3. Specialty Clinics
10.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
10.1.4. Others
10.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
11. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 by Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.1.1. Hospitals Pharmacy
11.1.1.1. Hospitals pharmacy market size and forecast, 2021-2031 (USD Million)
11.1.2. Retail Pharmacy
11.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
11.1.3. Ecommerce
11.1.3.1. Ecommerce market size and forecast, 2021-2031 (USD Million)
11.1.4. Others
11.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
12. North America Antibacterial Drugs Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. North America Antibacterial Drugs Market Size and Forecast By Drug Class
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. North America Antibacterial Drugs Market Size and Forecast By Prescription Type
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. North America Antibacterial Drugs Market Size and Forecast By Drug Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. North America Antibacterial Drugs Market Size and Forecast By Indication
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. North America Antibacterial Drugs Market Size and Forecast By Route of Administration
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. North America Antibacterial Drugs Market Size and Forecast By End-User
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. North America Antibacterial Drugs Market Size and Forecast By Distribution Channel
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. U.S. Antibacterial Drugs Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Canada Antibacterial Drugs Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
13. Europe Antibacterial Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Europe Antibacterial Drugs Market Size and Forecast By Drug Class
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Europe Antibacterial Drugs Market Size and Forecast By Prescription Type
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Europe Antibacterial Drugs Market Size and Forecast By Drug Type
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Europe Antibacterial Drugs Market Size and Forecast By Indication
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Europe Antibacterial Drugs Market Size and Forecast By Route of Administration
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Europe Antibacterial Drugs Market Size and Forecast By End-User
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Europe Antibacterial Drugs Market Size and Forecast By Distribution Channel
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. UK Antibacterial Drugs Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. Germany Antibacterial Drugs Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. France Antibacterial Drugs Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. Rest of Europe Antibacterial Drugs Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
14. Asia Pacific Antibacterial Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Asia-Pacific Antibacterial Drugs Market Size and Forecast By Drug Class
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Asia-Pacific Antibacterial Drugs Market Size and Forecast By Prescription Type
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Asia-Pacific Antibacterial Drugs Market Size and Forecast By Drug Type
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Asia-Pacific Antibacterial Drugs Market Size and Forecast By Indication
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Asia-Pacific Antibacterial Drugs Market Size and Forecast By Route of Administration
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Asia-Pacific Antibacterial Drugs Market Size and Forecast By End-User
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Asia-Pacific Antibacterial Drugs Market Size and Forecast By Distribution Channel
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. China Antibacterial Drugs Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. India Antibacterial Drugs Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. Japan Antibacterial Drugs Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
14.12. Rest of Asia Pacific Antibacterial Drugs Market
14.12.1.1. XX Driving/Opportunity Factor
14.12.1.2. XX Driving/Opportunity Factor
15. Latin America Antibacterial Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. Latin America Antibacterial Drugs Market Size and Forecast By Drug Class
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. Latin America Antibacterial Drugs Market Size and Forecast By Prescription Type
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. Latin America Antibacterial Drugs Market Size and Forecast By Drug Type
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. Latin America Antibacterial Drugs Market Size and Forecast By Indication
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. Latin America Antibacterial Drugs Market Size and Forecast By Route of Administration
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. Latin America Antibacterial Drugs Market Size and Forecast By End-User
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. Latin America Antibacterial Drugs Market Size and Forecast By Distribution Channel
15.9. Brazil Antibacterial Drugs Market
15.9.1.1. XX Driving/Opportunity Factor
15.9.1.2. XX Driving/Opportunity Factor
15.10. Mexico Antibacterial Drugs Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Rest of Latin America Antibacterial Drugs Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
16. MEA Antibacterial Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
16.1. Market Overview
16.2. MEA Antibacterial Drugs Market Size and Forecast By Drug Class
16.2.1.1. XX Driving/Opportunity Factor
16.2.1.2. XX Driving/Opportunity Factor
16.3. MEA Antibacterial Drugs Market Size and Forecast By Prescription Type
16.3.1.1. XX Driving/Opportunity Factor
16.3.1.2. XX Driving/Opportunity Factor
16.4. MEA Antibacterial Drugs Market Size and Forecast By Drug Type
16.4.1.1. XX Driving/Opportunity Factor
16.4.1.2. XX Driving/Opportunity Factor
16.5. MEA Antibacterial Drugs Market Size and Forecast By Indication
16.5.1.1. XX Driving/Opportunity Factor
16.5.1.2. XX Driving/Opportunity Factor
16.6. MEA Antibacterial Drugs Market Size and Forecast By Route of Administration
16.6.1.1. XX Driving/Opportunity Factor
16.6.1.2. XX Driving/Opportunity Factor
16.7. MEA Antibacterial Drugs Market Size and Forecast By End-User
16.7.1.1. XX Driving/Opportunity Factor
16.7.1.2. XX Driving/Opportunity Factor
16.8. MEA Antibacterial Drugs Market Size and Forecast By Distribution Channel
16.8.1.1. XX Driving/Opportunity Factor
16.8.1.2. XX Driving/Opportunity Factor
16.9. GCC Antibacterial Drugs Market
16.9.1.1. XX Driving/Opportunity Factor
16.9.1.2. XX Driving/Opportunity Factor
16.10. South Africa Antibacterial Drugs Market
16.10.1.1. XX Driving/Opportunity Factor
16.10.1.2. XX Driving/Opportunity Factor
16.11. Rest of MEA Antibacterial Drugs Market
16.11.1.1. XX Driving/Opportunity Factor
16.11.1.2. XX Driving/Opportunity Factor
17. Companies in the Antibacterial Drugs Market
17.1. Adenium Biotech ApS
17.1.1. Company Snapshot
17.1.2. Company Overview
17.1.3. Financial Performance (2015-2019)
17.1.3.1. Net Revenue
17.1.3.2. Gross Profit
17.1.3.3. Geographical Revenue, 2019
17.1.4. Product Offerings
17.1.5. Recent Initiatives (2017-2019)
17.2. Allecra Therapeutics GmbH
17.2.1. Company Snapshot
17.2.2. Company Overview
17.2.3. Financial Performance (2015-2019)
17.2.3.1. Net Revenue
17.2.3.2. Gross Profit
17.2.3.3. Geographical Revenue, 2019
17.2.4. Product Offerings
17.2.5. Recent Initiatives (2017-2019)
17.3. AstraZeneca
17.3.1. Company Snapshot
17.3.2. Company Overview
17.3.3. Financial Performance (2015-2019)
17.3.3.1. Net Revenue
17.3.3.2. Gross Profit
17.3.3.3. Geographical Revenue, 2019
17.3.4. Product Offerings
17.3.5. Recent Initiatives (2017-2019)
17.4. Bayer
17.4.1. Company Snapshot
17.4.2. Company Overview
17.4.3. Financial Performance (2015-2019)
17.4.3.1. Net Revenue
17.4.3.2. Gross Profit
17.4.3.3. Geographical Revenue, 2019
17.4.4. Product Offerings
17.4.5. Recent Initiatives (2017-2019)
17.5. BioVersys AG
17.5.1. Company Snapshot
17.5.2. Company Overview
17.5.3. Financial Performance (2015-2019)
17.5.3.1. Net Revenue
17.5.3.2. Gross Profit
17.5.3.3. Geographical Revenue, 2019
17.5.4. Product Offerings
17.5.5. Recent Initiatives (2017-2019)
17.6. Eli Lilly
17.6.1. Company Snapshot
17.6.2. Company Overview
17.6.3. Financial Performance (2015-2019)
17.6.3.1. Net Revenue
17.6.3.2. Gross Profit
17.6.3.3. Geographical Revenue, 2019
17.6.4. Product Offerings
17.6.5. Recent Initiatives (2017-2019)
17.7. GlaxoSmithKline (GSK)
17.7.1. Company Snapshot
17.7.2. Company Overview
17.7.3. Financial Performance (2015-2019)
17.7.3.1. Net Revenue
17.7.3.2. Gross Profit
17.7.3.3. Geographical Revenue, 2019
17.7.4. Product Offerings
17.7.5. Recent Initiatives (2017-2019)
17.8. Merck & Co.
17.8.1. Company Snapshot
17.8.2. Company Overview
17.8.3. Financial Performance (2015-2019)
17.8.3.1. Net Revenue
17.8.3.2. Gross Profit
17.8.3.3. Geographical Revenue, 2019
17.8.4. Product Offerings
17.8.5. Recent Initiatives (2017-2019)
17.9. Novartis
17.9.1. Company Snapshot
17.9.2. Company Overview
17.9.3. Financial Performance (2015-2019)
17.9.3.1. Net Revenue
17.9.3.2. Gross Profit
17.9.3.3. Geographical Revenue, 2019
17.9.4. Product Offerings
17.9.5. Recent Initiatives (2017-2019)
17.10. Pfizer
17.10.1. Company Snapshot
17.10.2. Company Overview
17.10.3. Financial Performance (2015-2019)
17.10.3.1. Net Revenue
17.10.3.2. Gross Profit
17.10.3.3. Geographical Revenue, 2019
17.10.4. Product Offerings
17.10.5. Recent Initiatives (2017-2019)
17.11. Other Notable Players
18. Conclusion
19. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antibacterial Drugs Market Drivers & Restraints 2021
Table 7. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Oral h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Antibacterial Drugs Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Antibacterial Drugs Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Antibacterial Drugs Market Forecast by Indication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Antibacterial Drugs Market Forecast by Indication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 168. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 178. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 183. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 188. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 193. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 198. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 199. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 248. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 249. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 250. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 251. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 252. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 253. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 254. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 255. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 256. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 257. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 258. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 259. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 260. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 261. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 262. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 263. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 264. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 265. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 266. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 267. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 268. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 269. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 270. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 271. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 272. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 273. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 274. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 275. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 276. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 277. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 278. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 279. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 280. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 281. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 282. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 283. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 284. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 285. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 286. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 287. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 402. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 403. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 404. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 405. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 406. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 407. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 408. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 409. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 410. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 411. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 412. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 413. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 414. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 415. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 416. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 417. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 418. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 419. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 420. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 421. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 422. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 423. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 424. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 425. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 426. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 427. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 428. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 429. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 430. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 431. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 432. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 433. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 434. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 435. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 436. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 437. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 438. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 439. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 440. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 441. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 442. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 443. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 444. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 445. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 446. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 447. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 448. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 449. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 450. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 451. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 452. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 453. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 454. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 455. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 456. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 457. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 458. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 459. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 460. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 461. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 462. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 463. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 464. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 465. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 466. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 467. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 468. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 469. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 470. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 471. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 472. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 473. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 474. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 475. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 476. Leading 10 Antibacterial Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 477. Adenium Biotech ApS Profile 2019 (CEO, HQ, Founded, Website)
Table 478. Adenium Biotech ApS Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 479. Allecra Therapeutics GmbH Profile 2019 (CEO, HQ, Founded, Website)
Table 480. Allecra Therapeutics GmbH Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 481. AstraZeneca Profile 2019 (CEO, HQ, Founded, Website)
Table 482. AstraZeneca.Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 483. Bayer Profile 2019 (CEO, HQ, Founded, Website)
Table 484. Bayer Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 485. BioVersys AG Profile 2019 (CEO, HQ, Founded, Website)
Table 486. BioVersys AG Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 487. Eli Lilly Profile 2019 (CEO, HQ, Founded, Website)
Table 488. Eli Lilly Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 489. GlaxoSmithKline (GSK) Profile 2019 (CEO, HQ, Founded, Website)
Table 490. GlaxoSmithKline (GSK) Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 491. Merck & Co. Profile 2019 (CEO, HQ, Founded, Website)
Table 492. Merck & Co. Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 493. Novartis Profile 2019 (CEO, HQ, Founded, Website)
Table 494. Novartis Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 495. Pfizer Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 496. Pfizer Corporation Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 497. Other Companies Involved in the Antibacterial Drugs Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Antibacterial Drugs Market Drivers & Restraints 2021
Figure 7. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 33. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Oral h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Antibacterial Drugs Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Antibacterial Drugs Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Antibacterial Drugs Market Forecast by Indication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Antibacterial Drugs Market Forecast by Indication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 168. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 178. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 183. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 188. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 193. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 198. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 228. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 243. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 244. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 245. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 246. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 247. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 248. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 249. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 250. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 251. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 252. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 253. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 254. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 255. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 256. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 257. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 258. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 259. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 260. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 261. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 262. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 263. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 264. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 265. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 266. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 267. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 268. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 269. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 270. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 271. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 272. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 273. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 274. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 275. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 276. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 277. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 278. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 279. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 280. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 281. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 282. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 283. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 284. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 285. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 286. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 287. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 402. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 403. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 404. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 405. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 406. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 407. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 408. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 409. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 410. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 411. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 412. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 413. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 414. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 415. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 416. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 417. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 418. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 419. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 420. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 421. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 422. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 423. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 424. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 425. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 426. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 427. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 428. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 429. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 430. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 431. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 432. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 433. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 434. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 435. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 436. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 437. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 438. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 439. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 440. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 441. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 442. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 443. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 444. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 445. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 446. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 447. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 448. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 449. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 450. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 451. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 452. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 453. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 454. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 455. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 456. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 457. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 458. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 459. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 460. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 461. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 462. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 463. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 464. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 465. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 466. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 467. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 468. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 469. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 470. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 471. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 472. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 473. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 474. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 475. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 476. Porter’s Five Force Analysis
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Antibacterial Drugs Market
2.1. Antibacterial Drugs Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Prescription Type Submarkets Definitions
3. Antibacterial Drugs Market Overview
3.1. Global Antibacterial Drugs Market Size and Forecast by Region
3.2. Global Antibacterial Drugs Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of bacterial diseases
3.3.1.2. Increasing consumptions of tobacco products
3.3.1.3. Growing number of FDA approvals coupled with launch of new products
3.3.1.4. Therapeutic advancements in antibacterial drugs
3.3.2. Market Restraints
3.3.2.1. Adherence to stringent regulatory norms
3.3.2.2. High cost of development
3.3.2.3. Product recall
3.3.3. Opportunities
3.3.3.1. Increasing strategic initiatives in antibacterial drugs market
3.3.3.2. Growing demand in emerging economies
3.3.4. Challenges
3.3.4.1. Increasing risk of side effects associated with antibacterial drugs
3.3.4.2. Increasing prices of API
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Antibacterial Drugs Market Analysis and Forecast 2021-2031, By Drug Class (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. B-lactam
4.1.1.1. B-lactam market size and forecast, 2021-2031 (USD Million)
4.1.2. Cephalosporin
4.1.2.1. Cephalosporin market size and forecast, 2021-2031 (USD Million)
4.1.3. Quinolones
4.1.3.1. Quinolones market size and forecast, 2021-2031 (USD Million)
4.1.4. Carbapenems
4.1.4.1. Carbapenems market size and forecast, 2021-2031 (USD Million)
4.1.5. Penicillin
4.1.5.1. Penicillin market size and forecast, 2021-2031 (USD Million)
4.1.6. Macrolides
4.1.6.1. Macrolides market size and forecast, 2021-2031 (USD Million)
4.1.7. Fluoroquinolones
4.1.7.1. Fluoroquinolones market size and forecast, 2021-2031 (USD Million)
4.1.8. Tetracyclines
4.1.8.1. Tetracyclines market size and forecast, 2021-2031 (USD Million)
4.1.9. Aminoglycosides
4.1.9.1. Aminoglycosides market size and forecast, 2021-2031 (USD Million)
4.1.10. Sulfonamides
4.1.10.1. Sulfonamides market size and forecast, 2021-2031 (USD Million)
4.1.11. Phenicols
4.1.11.1. Phenicols market size and forecast, 2021-2031 (USD Million)
4.1.12. Others
4.1.12.1. Others market size and forecast, 2021-2031 (USD Million)
5. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 By Prescription Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. OTC Antibacterial Drugs
5.1.1.1. OTC Antibacterial Drugs market size and forecast, 2021-2031 (USD Million)
5.1.2. Prescription based Antibacterial Drugs
5.1.2.1. Prescription based Antibacterial Drugs market size and forecast, 2021-2031 (USD Million)
6. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Approved-Drugs
6.1.1.1. Approved-Drugs market size and forecast, 2021-2031 (USD Million)
6.1.2. Off-label Drugs
6.1.2.1. Off-label Drugs market size and forecast, 2021-2031 (USD Million)
7. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 By Route of Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Oral
7.1.1.1. Oral market size and forecast, 2021-2031 (USD Million)
7.1.2. Topical
7.1.2.1. Topical market size and forecast, 2021-2031 (USD Million)
7.1.3. Parenteral
7.1.3.1. Parenteral market size and forecast, 2021-2031 (USD Million)
7.1.4. Others
7.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
8. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Generic Drugs
8.1.1.1. Generic Drugs market size and forecast, 2021-2031 (USD Million)
8.1.2. Branded Drugs
8.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
9. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 By Indication (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Hospital-Acquired Bacterial Pneumonia
9.1.1.1. Hospital-Acquired Bacterial Pneumonia market size and forecast, 2021-2031 (USD Million)
9.1.2. Ventilator-Associated Bacterial Pneumonia
9.1.2.1. Ventilator-Associated Bacterial Pneumonia market size and forecast, 2021-2031 (USD Million)
9.1.3. Complicated Urinary Tract Infections
9.1.3.1. Complicated Urinary Tract Infections market size and forecast, 2021-2031 (USD Million)
9.1.4. Others
9.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
10. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 by End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.1.1. Hospitals
10.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
10.1.2. Homecare
10.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
10.1.3. Specialty Clinics
10.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
10.1.4. Others
10.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
11. Global Antibacterial Drugs Market Analysis and Forecast, 2021-2031 by Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.1.1. Hospitals Pharmacy
11.1.1.1. Hospitals pharmacy market size and forecast, 2021-2031 (USD Million)
11.1.2. Retail Pharmacy
11.1.2.1. Retail Pharmacy market size and forecast, 2021-2031 (USD Million)
11.1.3. Ecommerce
11.1.3.1. Ecommerce market size and forecast, 2021-2031 (USD Million)
11.1.4. Others
11.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
12. North America Antibacterial Drugs Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. North America Antibacterial Drugs Market Size and Forecast By Drug Class
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. North America Antibacterial Drugs Market Size and Forecast By Prescription Type
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. North America Antibacterial Drugs Market Size and Forecast By Drug Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. North America Antibacterial Drugs Market Size and Forecast By Indication
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. North America Antibacterial Drugs Market Size and Forecast By Route of Administration
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. North America Antibacterial Drugs Market Size and Forecast By End-User
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. North America Antibacterial Drugs Market Size and Forecast By Distribution Channel
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. U.S. Antibacterial Drugs Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Canada Antibacterial Drugs Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
13. Europe Antibacterial Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Europe Antibacterial Drugs Market Size and Forecast By Drug Class
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Europe Antibacterial Drugs Market Size and Forecast By Prescription Type
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Europe Antibacterial Drugs Market Size and Forecast By Drug Type
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Europe Antibacterial Drugs Market Size and Forecast By Indication
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Europe Antibacterial Drugs Market Size and Forecast By Route of Administration
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Europe Antibacterial Drugs Market Size and Forecast By End-User
13.7.1.1. XX Driving/Opportunity Factor
13.7.1.2. XX Driving/Opportunity Factor
13.8. Europe Antibacterial Drugs Market Size and Forecast By Distribution Channel
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. UK Antibacterial Drugs Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. Germany Antibacterial Drugs Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
13.11. France Antibacterial Drugs Market
13.11.1.1. XX Driving/Opportunity Factor
13.11.1.2. XX Driving/Opportunity Factor
13.12. Rest of Europe Antibacterial Drugs Market
13.12.1.1. XX Driving/Opportunity Factor
13.12.1.2. XX Driving/Opportunity Factor
14. Asia Pacific Antibacterial Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. Asia-Pacific Antibacterial Drugs Market Size and Forecast By Drug Class
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. Asia-Pacific Antibacterial Drugs Market Size and Forecast By Prescription Type
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. Asia-Pacific Antibacterial Drugs Market Size and Forecast By Drug Type
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. Asia-Pacific Antibacterial Drugs Market Size and Forecast By Indication
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. Asia-Pacific Antibacterial Drugs Market Size and Forecast By Route of Administration
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. Asia-Pacific Antibacterial Drugs Market Size and Forecast By End-User
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. Asia-Pacific Antibacterial Drugs Market Size and Forecast By Distribution Channel
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. China Antibacterial Drugs Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. India Antibacterial Drugs Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
14.11. Japan Antibacterial Drugs Market
14.11.1.1. XX Driving/Opportunity Factor
14.11.1.2. XX Driving/Opportunity Factor
14.12. Rest of Asia Pacific Antibacterial Drugs Market
14.12.1.1. XX Driving/Opportunity Factor
14.12.1.2. XX Driving/Opportunity Factor
15. Latin America Antibacterial Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
15.1. Market Overview
15.2. Latin America Antibacterial Drugs Market Size and Forecast By Drug Class
15.2.1.1. XX Driving/Opportunity Factor
15.2.1.2. XX Driving/Opportunity Factor
15.3. Latin America Antibacterial Drugs Market Size and Forecast By Prescription Type
15.3.1.1. XX Driving/Opportunity Factor
15.3.1.2. XX Driving/Opportunity Factor
15.4. Latin America Antibacterial Drugs Market Size and Forecast By Drug Type
15.4.1.1. XX Driving/Opportunity Factor
15.4.1.2. XX Driving/Opportunity Factor
15.5. Latin America Antibacterial Drugs Market Size and Forecast By Indication
15.5.1.1. XX Driving/Opportunity Factor
15.5.1.2. XX Driving/Opportunity Factor
15.6. Latin America Antibacterial Drugs Market Size and Forecast By Route of Administration
15.6.1.1. XX Driving/Opportunity Factor
15.6.1.2. XX Driving/Opportunity Factor
15.7. Latin America Antibacterial Drugs Market Size and Forecast By End-User
15.7.1.1. XX Driving/Opportunity Factor
15.7.1.2. XX Driving/Opportunity Factor
15.8. Latin America Antibacterial Drugs Market Size and Forecast By Distribution Channel
15.9. Brazil Antibacterial Drugs Market
15.9.1.1. XX Driving/Opportunity Factor
15.9.1.2. XX Driving/Opportunity Factor
15.10. Mexico Antibacterial Drugs Market
15.10.1.1. XX Driving/Opportunity Factor
15.10.1.2. XX Driving/Opportunity Factor
15.11. Rest of Latin America Antibacterial Drugs Market
15.11.1.1. XX Driving/Opportunity Factor
15.11.1.2. XX Driving/Opportunity Factor
16. MEA Antibacterial Drugs Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
16.1. Market Overview
16.2. MEA Antibacterial Drugs Market Size and Forecast By Drug Class
16.2.1.1. XX Driving/Opportunity Factor
16.2.1.2. XX Driving/Opportunity Factor
16.3. MEA Antibacterial Drugs Market Size and Forecast By Prescription Type
16.3.1.1. XX Driving/Opportunity Factor
16.3.1.2. XX Driving/Opportunity Factor
16.4. MEA Antibacterial Drugs Market Size and Forecast By Drug Type
16.4.1.1. XX Driving/Opportunity Factor
16.4.1.2. XX Driving/Opportunity Factor
16.5. MEA Antibacterial Drugs Market Size and Forecast By Indication
16.5.1.1. XX Driving/Opportunity Factor
16.5.1.2. XX Driving/Opportunity Factor
16.6. MEA Antibacterial Drugs Market Size and Forecast By Route of Administration
16.6.1.1. XX Driving/Opportunity Factor
16.6.1.2. XX Driving/Opportunity Factor
16.7. MEA Antibacterial Drugs Market Size and Forecast By End-User
16.7.1.1. XX Driving/Opportunity Factor
16.7.1.2. XX Driving/Opportunity Factor
16.8. MEA Antibacterial Drugs Market Size and Forecast By Distribution Channel
16.8.1.1. XX Driving/Opportunity Factor
16.8.1.2. XX Driving/Opportunity Factor
16.9. GCC Antibacterial Drugs Market
16.9.1.1. XX Driving/Opportunity Factor
16.9.1.2. XX Driving/Opportunity Factor
16.10. South Africa Antibacterial Drugs Market
16.10.1.1. XX Driving/Opportunity Factor
16.10.1.2. XX Driving/Opportunity Factor
16.11. Rest of MEA Antibacterial Drugs Market
16.11.1.1. XX Driving/Opportunity Factor
16.11.1.2. XX Driving/Opportunity Factor
17. Companies in the Antibacterial Drugs Market
17.1. Adenium Biotech ApS
17.1.1. Company Snapshot
17.1.2. Company Overview
17.1.3. Financial Performance (2015-2019)
17.1.3.1. Net Revenue
17.1.3.2. Gross Profit
17.1.3.3. Geographical Revenue, 2019
17.1.4. Product Offerings
17.1.5. Recent Initiatives (2017-2019)
17.2. Allecra Therapeutics GmbH
17.2.1. Company Snapshot
17.2.2. Company Overview
17.2.3. Financial Performance (2015-2019)
17.2.3.1. Net Revenue
17.2.3.2. Gross Profit
17.2.3.3. Geographical Revenue, 2019
17.2.4. Product Offerings
17.2.5. Recent Initiatives (2017-2019)
17.3. AstraZeneca
17.3.1. Company Snapshot
17.3.2. Company Overview
17.3.3. Financial Performance (2015-2019)
17.3.3.1. Net Revenue
17.3.3.2. Gross Profit
17.3.3.3. Geographical Revenue, 2019
17.3.4. Product Offerings
17.3.5. Recent Initiatives (2017-2019)
17.4. Bayer
17.4.1. Company Snapshot
17.4.2. Company Overview
17.4.3. Financial Performance (2015-2019)
17.4.3.1. Net Revenue
17.4.3.2. Gross Profit
17.4.3.3. Geographical Revenue, 2019
17.4.4. Product Offerings
17.4.5. Recent Initiatives (2017-2019)
17.5. BioVersys AG
17.5.1. Company Snapshot
17.5.2. Company Overview
17.5.3. Financial Performance (2015-2019)
17.5.3.1. Net Revenue
17.5.3.2. Gross Profit
17.5.3.3. Geographical Revenue, 2019
17.5.4. Product Offerings
17.5.5. Recent Initiatives (2017-2019)
17.6. Eli Lilly
17.6.1. Company Snapshot
17.6.2. Company Overview
17.6.3. Financial Performance (2015-2019)
17.6.3.1. Net Revenue
17.6.3.2. Gross Profit
17.6.3.3. Geographical Revenue, 2019
17.6.4. Product Offerings
17.6.5. Recent Initiatives (2017-2019)
17.7. GlaxoSmithKline (GSK)
17.7.1. Company Snapshot
17.7.2. Company Overview
17.7.3. Financial Performance (2015-2019)
17.7.3.1. Net Revenue
17.7.3.2. Gross Profit
17.7.3.3. Geographical Revenue, 2019
17.7.4. Product Offerings
17.7.5. Recent Initiatives (2017-2019)
17.8. Merck & Co.
17.8.1. Company Snapshot
17.8.2. Company Overview
17.8.3. Financial Performance (2015-2019)
17.8.3.1. Net Revenue
17.8.3.2. Gross Profit
17.8.3.3. Geographical Revenue, 2019
17.8.4. Product Offerings
17.8.5. Recent Initiatives (2017-2019)
17.9. Novartis
17.9.1. Company Snapshot
17.9.2. Company Overview
17.9.3. Financial Performance (2015-2019)
17.9.3.1. Net Revenue
17.9.3.2. Gross Profit
17.9.3.3. Geographical Revenue, 2019
17.9.4. Product Offerings
17.9.5. Recent Initiatives (2017-2019)
17.10. Pfizer
17.10.1. Company Snapshot
17.10.2. Company Overview
17.10.3. Financial Performance (2015-2019)
17.10.3.1. Net Revenue
17.10.3.2. Gross Profit
17.10.3.3. Geographical Revenue, 2019
17.10.4. Product Offerings
17.10.5. Recent Initiatives (2017-2019)
17.11. Other Notable Players
18. Conclusion
19. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antibacterial Drugs Market Drivers & Restraints 2021
Table 7. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 33. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Oral h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Antibacterial Drugs Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Antibacterial Drugs Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Antibacterial Drugs Market Forecast by Indication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Antibacterial Drugs Market Forecast by Indication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 158. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 163. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 167. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 168. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 177. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 178. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 179. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 180. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 181. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 183. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 187. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 188. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 189. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 190. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 191. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 193. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 195. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 198. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 199. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 202. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 233. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 234. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 235. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 236. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 237. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 238. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 239. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 240. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 241. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 242. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 243. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 244. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 245. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 246. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 247. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 248. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 249. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 250. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 251. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 252. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 253. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 254. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 255. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 256. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 257. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 258. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 259. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 260. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 261. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 262. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 263. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 264. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 265. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 266. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 267. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 268. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 269. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 270. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 271. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 272. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 273. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 274. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 275. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 276. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 277. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 278. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 279. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 280. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 281. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 282. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 283. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 284. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 285. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 286. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 287. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 402. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 403. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 404. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 405. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 406. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 407. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 408. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 409. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 410. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 411. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 412. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 413. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 414. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 415. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 416. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 417. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 418. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 419. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 420. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 421. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 422. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 423. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 424. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 425. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 426. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 427. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 428. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 429. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 430. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 431. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 432. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 433. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 434. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 435. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 436. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 437. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 438. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 439. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 440. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 441. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 442. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 443. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 444. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 445. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 446. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 447. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 448. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 449. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 450. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 451. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 452. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 453. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 454. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 455. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 456. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 457. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 458. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 459. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 460. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 461. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 462. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 463. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 464. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 465. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 466. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 467. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 468. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 469. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 470. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 471. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 472. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 473. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 474. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 475. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 476. Leading 10 Antibacterial Drugs Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 477. Adenium Biotech ApS Profile 2019 (CEO, HQ, Founded, Website)
Table 478. Adenium Biotech ApS Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 479. Allecra Therapeutics GmbH Profile 2019 (CEO, HQ, Founded, Website)
Table 480. Allecra Therapeutics GmbH Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 481. AstraZeneca Profile 2019 (CEO, HQ, Founded, Website)
Table 482. AstraZeneca.Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 483. Bayer Profile 2019 (CEO, HQ, Founded, Website)
Table 484. Bayer Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 485. BioVersys AG Profile 2019 (CEO, HQ, Founded, Website)
Table 486. BioVersys AG Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 487. Eli Lilly Profile 2019 (CEO, HQ, Founded, Website)
Table 488. Eli Lilly Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 489. GlaxoSmithKline (GSK) Profile 2019 (CEO, HQ, Founded, Website)
Table 490. GlaxoSmithKline (GSK) Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 491. Merck & Co. Profile 2019 (CEO, HQ, Founded, Website)
Table 492. Merck & Co. Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 493. Novartis Profile 2019 (CEO, HQ, Founded, Website)
Table 494. Novartis Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 495. Pfizer Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 496. Pfizer Corporation Antibacterial Drugs Product Offering (Segment, Product Offerings)
Table 497. Other Companies Involved in the Antibacterial Drugs Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Antibacterial Drugs Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Antibacterial Drugs Market Drivers & Restraints 2021
Figure 7. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. B-lactam Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Cephalosporin Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Quinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Carbapenems Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 33. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Penicillin Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Macrolides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Fluoroquinolones Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Tetracyclines Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Aminoglycosides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Sulfonamides Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Phenicols Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. OTC Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Prescription based Antibacterial Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Oral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Oral h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Topical Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Parenteral Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Antibacterial Drugs Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Antibacterial Drugs Market Forecast by Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Antibacterial Drugs Market Forecast by Indication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Antibacterial Drugs Market Forecast by Indication Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Hospital-Acquired Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Ventilator-Associated Bacterial Pneumonia Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Complicated Urinary Tract Infections Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 158. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 163. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 168. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 173. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 178. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 183. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. Hospital Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 188. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. Retail Pharmacy Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 193. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. Ecommerce Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 198. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 203. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. North America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. North America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. North America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. North America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. North America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 228. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. North America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 233. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 234. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 235. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 236. North America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 237. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 238. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 239. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 240. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 241. North America Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 242. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 243. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 244. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 245. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 246. US Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 247. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 248. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 249. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 250. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 251. Canada Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 252. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 253. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 254. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 255. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 256. Europe Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 257. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 258. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 259. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 260. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 261. Europe Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 262. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 263. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 264. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 265. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 266. Europe Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 267. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 268. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 269. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 270. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 271. Europe Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 272. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 273. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 274. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 275. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 276. Europe Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 277. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 278. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 279. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 280. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 281. Europe Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 282. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 283. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 284. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 285. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 286. Europe Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 287. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Europe Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. UK Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. Germany Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. France Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. Rest of Europe Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Asia Pacific Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Asia Pacific Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Asia Pacific Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Asia Pacific Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Asia Pacific Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Asia Pacific Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Asia Pacific Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Asia Pacific Antibacterial Drugs Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. China Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. India Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Japan Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. RoAPAC Antibacterial Drugs Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Middle East Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Middle East Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Middle East Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Middle East Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Middle East Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Middle East Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 402. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 403. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 404. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 405. Middle East Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 406. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 407. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 408. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 409. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 410. Latin America Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 411. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 412. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 413. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 414. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 415. Latin America Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 416. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 417. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 418. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 419. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 420. Latin America Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 421. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 422. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 423. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 424. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 425. Latin America Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 426. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 427. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 428. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 429. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 430. Latin America Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 431. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 432. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 433. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 434. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 435. Latin America Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 436. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 437. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 438. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 439. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 440. Latin America Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 441. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 442. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 443. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 444. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 445. Africa Antibacterial Drugs Market Forecast By Drug Class 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 446. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 447. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 448. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 449. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 450. Africa Antibacterial Drugs Market Forecast by Prescription Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 451. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 452. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 453. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 454. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 455. Africa Antibacterial Drugs Market Forecast by Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 456. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 457. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 458. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 459. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 460. Africa Antibacterial Drugs Market Forecast by Indication 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 461. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 462. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 463. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 464. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 465. Africa Antibacterial Drugs Market Forecast by Route of Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 466. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 467. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 468. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 469. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 470. Africa Antibacterial Drugs Market Forecast by End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 471. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 472. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 473. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 474. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 475. Africa Antibacterial Drugs Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 476. Porter’s Five Force Analysis
Companies Profiled in the Report
1. Adenium Biotech ApS
2. Allecra Therapeutics GmbH
3. AstraZeneca
4. Bayer
5. BioVersys AG
6. Eli Lilly
7. GlaxoSmithKline (GSK)
8. Merck & Co.
9. Novartis
10. Pfizer
List of Companies Mentioned in the Report
1. Abbott Laboratories
2. AbbVie
3. SHIONOGI Co., Ltd.
4. Achaogen
5. Actavis
6. Actelion
7. Affinium Pharmaceutical
8. AiCuris GmbH & Co. KG
9. Alcon
10. Alkem Laboratories
11. Allergan
12. Allied Pharma
13. Apotex
14. APP Pharmaceuticals
15. Aptalis Pharma
16. Aquapharm Biodiscovery
17. Cempra Pharmaceuticals
18. Cipla
19. Claris Lifesciences
20. Cornerstone Biopharma
21. Cornerstone Therapeutics
22. Corona Remedies
23. Eli Lilly
24. Gate Pharma
25. Gilead Sciences
26. Glenmark
27. GlycoVaxyn
28. GlaxoSmithKline (GSK)
29. Hetero
30. Hi-Tech Pharma
31. Hikma Farmaceutica
32. Hospira
33. Macleod Pharmaceuticals
34. Microlabs
35. Nalneva
36. Novartis
37. Novexel
38. Paratek Pharmaceuticals
39. Pfizer
40. Ranbaxy
41. Roche
42. Sagent Pharmaceuticals
43. Sandoz
44. Sanofi
45. Sequella
46. Shanghai MengKe Pharmaceuticals
47. Shionogi
48. Shire
49. Sidmak Labs
50. Solitaire Pharmacia
51. Specialised Therapeutics Australia
List of Organizations Mentioned in the Report:
1. Agência Nacional de Vigilância Sanitária (ANVISA)
2. Duke University
3. European Medicines Agency (EMA)
4. Food and Drug Administration (FDA)
5. Ministry of Health, Labour and Welfare (MHLW)
6. Michigan State University
7. National Institute for Health and Clinical Excellence (NICE)
8. National Institutes of Health (NIH)
9. University of Connecticut
10. World Health Organization (WHO)
11. The National Medical Products Administration (NMPA)
12. Indian Council of Medical Research (ICMR)
13. The Therapeutic Goods Administration
14. The Federal Institute for Drugs and Medical Devices (BfArM)
15. Pharmaceuticals and Medical Devices Agency (PMDA)
16. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
17. Ministry of Health, Labour & Welfare(MHLW)
18. Medicines and Healthcare Products Regulatory Agency (MHRA)
19. Centre for Pharmaceutical Administration Health Sciences Authority
20. Central Drug Standard Control Organization (CDSCO)
1. Adenium Biotech ApS
2. Allecra Therapeutics GmbH
3. AstraZeneca
4. Bayer
5. BioVersys AG
6. Eli Lilly
7. GlaxoSmithKline (GSK)
8. Merck & Co.
9. Novartis
10. Pfizer
List of Companies Mentioned in the Report
1. Abbott Laboratories
2. AbbVie
3. SHIONOGI Co., Ltd.
4. Achaogen
5. Actavis
6. Actelion
7. Affinium Pharmaceutical
8. AiCuris GmbH & Co. KG
9. Alcon
10. Alkem Laboratories
11. Allergan
12. Allied Pharma
13. Apotex
14. APP Pharmaceuticals
15. Aptalis Pharma
16. Aquapharm Biodiscovery
17. Cempra Pharmaceuticals
18. Cipla
19. Claris Lifesciences
20. Cornerstone Biopharma
21. Cornerstone Therapeutics
22. Corona Remedies
23. Eli Lilly
24. Gate Pharma
25. Gilead Sciences
26. Glenmark
27. GlycoVaxyn
28. GlaxoSmithKline (GSK)
29. Hetero
30. Hi-Tech Pharma
31. Hikma Farmaceutica
32. Hospira
33. Macleod Pharmaceuticals
34. Microlabs
35. Nalneva
36. Novartis
37. Novexel
38. Paratek Pharmaceuticals
39. Pfizer
40. Ranbaxy
41. Roche
42. Sagent Pharmaceuticals
43. Sandoz
44. Sanofi
45. Sequella
46. Shanghai MengKe Pharmaceuticals
47. Shionogi
48. Shire
49. Sidmak Labs
50. Solitaire Pharmacia
51. Specialised Therapeutics Australia
List of Organizations Mentioned in the Report:
1. Agência Nacional de Vigilância Sanitária (ANVISA)
2. Duke University
3. European Medicines Agency (EMA)
4. Food and Drug Administration (FDA)
5. Ministry of Health, Labour and Welfare (MHLW)
6. Michigan State University
7. National Institute for Health and Clinical Excellence (NICE)
8. National Institutes of Health (NIH)
9. University of Connecticut
10. World Health Organization (WHO)
11. The National Medical Products Administration (NMPA)
12. Indian Council of Medical Research (ICMR)
13. The Therapeutic Goods Administration
14. The Federal Institute for Drugs and Medical Devices (BfArM)
15. Pharmaceuticals and Medical Devices Agency (PMDA)
16. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
17. Ministry of Health, Labour & Welfare(MHLW)
18. Medicines and Healthcare Products Regulatory Agency (MHRA)
19. Centre for Pharmaceutical Administration Health Sciences Authority
20. Central Drug Standard Control Organization (CDSCO)
Download sample pages
Complete the form below to download your free sample pages for Antibacterial Drugs Market Report 2021-2031Related reports
Non-alcoholic Fatty Liver Disease (NAFLD) & NASH Market Report 2021-2031
The report study aims to explore the market drivers, restraints and also market opportunities facing non-alcoholic fatty liver disease &...Full DetailsPublished: 17 February 2021Antihypertensive Drugs Market Report 2021-2031
Hypertensive is the most common disease around the world. However, number of people suffering from hypertensive has increased very significantly...Full DetailsPublished: 01 January 1970Drugs of Abuse Testing Market Report 2021-2031
Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise...Full DetailsPublished: 01 January 1970Cholesterol Lowering Drugs Market Report 2021-2031
Increasing risk of high cholesterol and associated diseases has lead various leading drug manufactures to increase their research and development...Full DetailsPublished: 01 January 1970
Download sample pages
Complete the form below to download your free sample pages for Antibacterial Drugs Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes 3D Cell Culture and 3D Bioprinting Market Report 2023-2033
The global 3D Cell Culture and 3D Bioprinting market is valued at US$2,277.2 million in 2023 and is projected to grow at a CAGR of 17.8% during the forecast period 2023-2033.
03 October 2023
Visiongain Publishes Bioreactors Market Report 2023-2033
The global Bioreactors market was estimated to be valued at US$9,977.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
29 September 2023
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
